Eagle Bay Advisors’s Takeda Pharmaceutical TAK Stock Holding History

Eagle Bay Advisors’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-142	Closed	-$2K	–	898
2021 Q4	$2K	Sell	142 -142	-50%	-$1.99K	﹤0.01%	941
2021 Q3	$4K	Buy	+284	New	+$4.77K	﹤0.01%	881

Other funds holding TAK

Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Eagle Bay Advisors's TAK Position: Q1 2022 in Review

Eagle Bay Advisors sold out of Takeda Pharmaceutical (TAK) in Q1 2022, closing a stake of 142 shares — an estimated $2K sold.

Eagle Bay Advisors first reported a position in TAK in Q3 2021 and held it in 2 quarters. The position peaked at $4K in Q3 2021. 288 funds tracked by Wall St. Rank hold TAK as of Q1 2022.

Eagle Bay Advisors reported no remaining Takeda Pharmaceutical position as of Q1 2022 after selling out during the quarter.
Eagle Bay Advisors sold 142 Takeda Pharmaceutical shares in Q1 2022, an estimated $2K.
Eagle Bay Advisors first reported a position in Takeda Pharmaceutical in Q3 2021 and held it in 2 quarters.
Eagle Bay Advisors's Takeda Pharmaceutical position peaked at $4K in Q3 2021.
288 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2022.

Based on Eagle Bay Advisors's 13F filing for Q1 2022, filed 11 May 2022.